{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007060","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.456111+00:00","generated_at":"2026-06-02T21:33:31.709268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva","bullets":["Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).","Cash $37.9M as of March 31, 2024 vs $13.5M at Dec 31, 2023, aided by $35M credit agreement with Innoviva arm.","Loan bears 14% annual interest, matures June 4, 2025; principal and interest payable at maturity.","Phase 2a diSArm (AP-SA02) and Phase 2 Tail wind (AP-PA02) advancing; enrollment on track.","cGMP manufacturing build-out expected mid-2024; R&D labs and admin space already operational."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007060","json":"https://secwatch.observer/filing/0001558370-24-007060.json","markdown":"https://secwatch.observer/filing/0001558370-24-007060.md","text":"https://secwatch.observer/filing/0001558370-24-007060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/0001558370-24-007060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/armp-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:33:31.709268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f3f4ff3ac7629dd20a6966c07e414ba5607ba2e","claim":"Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/0001558370-24-007060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}